Lexaria Bioscience Corp
lexariabioscience.comWhat Do They Do?
Licenses DehydraTECH, an oral drug-delivery technology, to pharmaceutical and other product companies, and provides formulation and manufacturing services for their products.
10-K for FY2025, filed Nov 28, 2025Lexaria Bioscience Corp. is a biotechnology company dedicated to the enhancement of the bioavailability of a diverse and broad range of…View ↗
DehydraTECH is a technology incorporated into the formulation and manufacturing process of new or existing orally ingestible products. The…View ↗
Lexaria supports our licensee’s products with our technology. A part of our business plan is to encourage new and existing industry…View ↗
Lexaria’s business operations include technology licensing agreements where corporate licensees implement DehydraTECH under license within…View ↗
How Do They Make Money?
Licensees pay for exclusive rights when DehydraTECH is transferred, fixed minimum fees over the period they cover, and any sales-based royalties when their products sell; B2B customers pay for intermediate products when manufacturing is complete.
10-K for FY2025, filed Nov 28, 2025Our revenues from licenses that grant exclusive rights to use our intellectual property, which we consider functional IP, are recognized at…View ↗
The Company may also earn sales-based or usage-based royalties from its licensing contracts. The Company recognizes usage fees in the…View ↗
Third Party Contracted ManufacturingView ↗
Year Ended August 31, 2025 2024 IP Licensing $ 696,000 $ 457,990 B2B 9,923 5,388 Other - 900 Total $ 705,923 $ 464,278View ↗
$705.9K
-
10-K for FY2025, filed Nov 28, 2025
$705.9K ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
IP Licensing
Mix
10-K for FY2025, filed Nov 28, 2025 |
99% |
IP Licensing, FY2025
$696K Sources
|
Mix |
|
B2B
Sold outright
|
1.4% |
B2B, FY2025
$9.9K Sources
|
Sold outright |
|
Other
|
0.0% |
Other, FY2025
$0 Sources
|
Who Are Their Customers?
Corporate licensees use DehydraTECH in their products; the company also does formulation work for third parties and supplies intermediate CBD products for customers to incorporate into their products.
10-K for FY2025, filed Nov 28, 2025
Do Revenues Turn Into Profits?
No. It lost $11.9M in FY2025.
10-K for FY2025, filed Nov 28, 2025
−$11.9MView ↗
10-K for FY2025, filed Nov 28, 2025
−$11.9MView ↗
10-K for FY2025, filed Nov 28, 2025
−$10.5MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q3 FY2026, filed Jul 13, 2026
−$2MView ↗
- ▼ −47% (Loss)
- vs −$3.8M in Q3 FY2025
-
Aug 17, 2026
Nasdaq confirmed Lexaria had regained bid-price compliance
The confirmation canceled the requested hearing, and the company’s shares would continue trading on Nasdaq.
Sources
8-K, filed Aug 17, 2026
Cure of Nasdaq Bid Price DeficiencyView ↗
-
Aug 10, 2026
Nasdaq notified Lexaria that it would delist its shares
Lexaria requested a hearing to appeal; the notice followed a failure to regain compliance with the minimum bid-price rule.
Sources
8-K, filed Aug 10, 2026
Nasdaq Delisting NotificationView ↗
Flat. Revenue was $705.9K in FY2025, about the same as the $722.7K of FY2021.
Loading...
